{"id":63125,"date":"2026-04-14T20:54:09","date_gmt":"2026-04-14T12:54:09","guid":{"rendered":"https:\/\/flcube.com\/?p=63125"},"modified":"2026-04-14T20:54:10","modified_gmt":"2026-04-14T12:54:10","slug":"cttq-and-teva-partner-on-treanda-commercialization-to-expand-bendamustine-access-in-chinas-nhl-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63125","title":{"rendered":"CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China&#8217;s NHL Market"},"content":{"rendered":"\n<p><strong>Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ)<\/strong>, a subsidiary of <strong>Sino Biopharmaceutical Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>), has formed a strategic partnership with <strong>Israel-based Teva Pharmaceutical Industries Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/TEVA:NYSE\">NASDAQ: TEVA<\/a>) to jointly advance the <strong>commercialization of Treanda (bendamustine)<\/strong> in the <strong>mainland China market<\/strong>. The collaboration aims to expand market access and address unmet clinical needs in <strong>indolent B-cell non-Hodgkin lymphoma (NHL)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure\">Partnership Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Chinese Partner<\/strong><\/td><td>Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ)<\/td><\/tr><tr><td><strong>Parent Company<\/strong><\/td><td>Sino Biopharmaceutical Ltd. (HKG: 1177)<\/td><\/tr><tr><td><strong>International Partner<\/strong><\/td><td>Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Treanda (bendamustine) \u2013 lymphoma treatment<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Approved in China since 2018<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Indolent B-cell NHL progressing during\/after rituximab-containing regimens<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-market-position\">Product Profile &amp; Market Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Origin:<\/strong> Developed and originated by Teva Pharmaceutical Industries<\/li>\n\n\n\n<li><strong>Approval Milestone:<\/strong> Received Chinese regulatory approval in 2018<\/li>\n\n\n\n<li><strong>Therapeutic Area:<\/strong> Hematologic oncology \u2013 specifically indolent B-cell non-Hodgkin lymphoma<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Patients with disease progression during or after rituximab or rituximab-containing regimens<\/li>\n\n\n\n<li><strong>Clinical Significance:<\/strong> Addresses critical treatment gap in relapsed\/refractory indolent NHL setting<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-responsibilities\">Commercial Responsibilities<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-cttq-role\">CTTQ Role<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Responsibility:<\/strong> Lead commercialization and promotion activities in mainland China<\/li>\n\n\n\n<li><strong>Market Expertise:<\/strong> Leverage established oncology sales infrastructure and hospital relationships<\/li>\n\n\n\n<li><strong>Local Capabilities:<\/strong> Navigate China&#8217;s complex healthcare system and reimbursement landscape<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-joint-collaboration-areas\">Joint Collaboration Areas<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Expansion:<\/strong> Broaden geographic and institutional reach across China<\/li>\n\n\n\n<li><strong>Terminal Coverage:<\/strong> Enhance penetration in key treatment centers and hospitals<\/li>\n\n\n\n<li><strong>Patient Access:<\/strong> Improve affordability and availability through strategic pricing and distribution initiatives<\/li>\n\n\n\n<li><strong>Clinical Education:<\/strong> Support physician awareness and appropriate patient identification<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-sino-biopharmaceutical-cttq\">For Sino Biopharmaceutical\/CTTQ<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology Portfolio Enhancement:<\/strong> Strengthens position in hematologic malignancies segment<\/li>\n\n\n\n<li><strong>International Partnership:<\/strong> Validates CTTQ&#8217;s commercial capabilities among global pharmaceutical companies<\/li>\n\n\n\n<li><strong>Revenue Diversification:<\/strong> Adds established oncology product with proven market demand<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-teva-pharmaceutical\">For Teva Pharmaceutical<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Market Access:<\/strong> Leverages CTTQ&#8217;s local expertise to maximize commercial potential<\/li>\n\n\n\n<li><strong>Operational Efficiency:<\/strong> Reduces need for direct commercial infrastructure investment in China<\/li>\n\n\n\n<li><strong>Focus Optimization:<\/strong> Allows Teva to concentrate resources on core global markets while maintaining China presence<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China NHL Market:<\/strong> Estimated at RMB 3.5 billion ($500 million) annually for indolent B-cell NHL treatments<\/li>\n\n\n\n<li><strong>Treatment Landscape:<\/strong> Limited options for rituximab-refractory patients create premium positioning opportunity<\/li>\n\n\n\n<li><strong>Reimbursement Status:<\/strong> National Reimbursement Drug List (NRDL) inclusion enhances patient access and market penetration potential<\/li>\n\n\n\n<li><strong>Competitive Environment:<\/strong> Established bendamustine market with room for expanded utilization through improved access initiatives<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms\">Financial Terms<\/h2>\n\n\n\n<p>Specific financial terms of the commercialization agreement were not disclosed. Typical arrangements in such partnerships include upfront payments, milestone achievements, and royalty structures based on sales performance.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercial expectations, market expansion, and partnership benefits for Treanda in China. Actual results may differ due to risks including market competition, reimbursement changes, regulatory developments, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63126,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[661,908,313,1071],"class_list":["post-63125","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-chia-tai-tianqing-pharmaceutical","tag-hkg-1177","tag-sino-biopharmaceutical","tag-teva-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China&#039;s NHL Market - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), has formed a strategic partnership with Israel-based Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) to jointly advance the commercialization of Treanda (bendamustine) in the mainland China market. The collaboration aims to expand market access and address unmet clinical needs in indolent B-cell non-Hodgkin lymphoma (NHL).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63125\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China&#039;s NHL Market\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), has formed a strategic partnership with Israel-based Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) to jointly advance the commercialization of Treanda (bendamustine) in the mainland China market. The collaboration aims to expand market access and address unmet clinical needs in indolent B-cell non-Hodgkin lymphoma (NHL).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63125\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-14T12:54:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-14T12:54:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1404-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63125#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63125\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China&#8217;s NHL Market\",\"datePublished\":\"2026-04-14T12:54:09+00:00\",\"dateModified\":\"2026-04-14T12:54:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63125\"},\"wordCount\":461,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63125#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1404-1.webp\",\"keywords\":[\"Chia Tai Tianqing Pharmaceutical\",\"HKG: 1177\",\"Sino Biopharmaceutical\",\"Teva Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63125#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63125\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63125\",\"name\":\"CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China's NHL Market - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63125#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63125#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1404-1.webp\",\"datePublished\":\"2026-04-14T12:54:09+00:00\",\"dateModified\":\"2026-04-14T12:54:10+00:00\",\"description\":\"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), has formed a strategic partnership with Israel-based Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) to jointly advance the commercialization of Treanda (bendamustine) in the mainland China market. The collaboration aims to expand market access and address unmet clinical needs in indolent B-cell non-Hodgkin lymphoma (NHL).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63125#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63125\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63125#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1404-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1404-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China's NHL Market\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63125#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China&#8217;s NHL Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China's NHL Market - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), has formed a strategic partnership with Israel-based Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) to jointly advance the commercialization of Treanda (bendamustine) in the mainland China market. The collaboration aims to expand market access and address unmet clinical needs in indolent B-cell non-Hodgkin lymphoma (NHL).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63125","og_locale":"en_US","og_type":"article","og_title":"CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China's NHL Market","og_description":"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), has formed a strategic partnership with Israel-based Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) to jointly advance the commercialization of Treanda (bendamustine) in the mainland China market. The collaboration aims to expand market access and address unmet clinical needs in indolent B-cell non-Hodgkin lymphoma (NHL).","og_url":"https:\/\/flcube.com\/?p=63125","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-14T12:54:09+00:00","article_modified_time":"2026-04-14T12:54:10+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1404-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63125#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63125"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China&#8217;s NHL Market","datePublished":"2026-04-14T12:54:09+00:00","dateModified":"2026-04-14T12:54:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63125"},"wordCount":461,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63125#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1404-1.webp","keywords":["Chia Tai Tianqing Pharmaceutical","HKG: 1177","Sino Biopharmaceutical","Teva Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63125#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63125","url":"https:\/\/flcube.com\/?p=63125","name":"CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China's NHL Market - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63125#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63125#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1404-1.webp","datePublished":"2026-04-14T12:54:09+00:00","dateModified":"2026-04-14T12:54:10+00:00","description":"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), has formed a strategic partnership with Israel-based Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) to jointly advance the commercialization of Treanda (bendamustine) in the mainland China market. The collaboration aims to expand market access and address unmet clinical needs in indolent B-cell non-Hodgkin lymphoma (NHL).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63125#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63125"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63125#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1404-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1404-1.webp","width":1080,"height":608,"caption":"CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China's NHL Market"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63125#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China&#8217;s NHL Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1404-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63125"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63125\/revisions"}],"predecessor-version":[{"id":63127,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63125\/revisions\/63127"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63126"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}